Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.The Debiopharm Group and Cambridge Antibody Technology have entered into a worldwide licensing agreement to develop SC-1 for gastric cancer and all derivative products generated from SC-1 technology.
Subscribe to our email newsletter
SC-1, developed by Debiopharm, is a fully human monoclonal IgM antibody that targets CD55SC-1, a cell surface receptor specifically expressed on gastric carcinoma cells. Under the terms of the agreement, Debiopharm will receive upfront and milestone payments from CAT as well as royalties on potential future sales.
“CAT’s expertise in the development of monoclonal antibodies gives us confidence for the future of SC-1 as a potential treatment for gastric cancer. As most patients diagnosed with stomach cancer fail to be cured by gastric resection, and most trials of pre- or post-surgery chemotherapy show no improvement in survival rates, there is a definite need for better treatment options,” said Loic Maurel, CEO of The Debiopharm Group Canadian subsidiary.
SC-1 has completed a phase I/II study in 51 resectable gastric cancer patients. SC-1 has been granted orphan drug designation by the FDA for gastric cancer.